Bio-Rad Laboratories, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BIO research report →
Range $310 – $390
Price Chart
About the company
Bio-Rad Laboratories, Inc. , established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America.
- CEO
- Norman D. Schwartz
- IPO
- 1980
- Employees
- 7,450
- HQ
- Hercules, CA, US
Get TickerSpark's AI analysis on BIO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $9.65B
- P/E
- 9.89
- Fwd P/E
- 35.95
- PEG
- 0.03
- P/S
- 3.91
- P/B
- 1.33
- EV/EBITDA
- 7.46
- Div Yield
- 0.00%
- Gross Margin
- 51.26%
- Op Margin
- 4.59%
- Net Margin
- 39.45%
- ROE
- 14.07%
- ROIC
- 0.90%
Latest fiscal year · YoY change
- Revenue
- $2.58B+0.7%
- Gross Profit
- $1.34B-2.6%
- Op Income
- $270.50M
- Net Income
- $759.90M+141.2%
- EPS
- $27.87+142.6%
- OCF Growth
- +16.9%
- FCF Growth
- +40.7%
- 52W High
- $396.23
- 52W Low
- $236.73
- 50D MA
- $371.83
- 200D MA
- $318.29
- Beta
- 1.06
- RSI (14)
- 43
- Avg Volume
- 260.18K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Bio-Rad posted modest Q3 revenue growth, improved non-GAAP margins, and reiterated 2026 guidance while pointing to continued progress in ddPCR and diagnostics.· November 4, 2026
- Q3 revenue was approximately $656 million, up 0.5% reported and 0.7% currency-neutral, marking the first currency-neutral growth quarter of 2026.
- Non-GAAP gross margin improved to 54.5% from 53.5% a year ago, and non-GAAP operating margin rose to 12.8% from 11.8%.
- ddPCR remained a bright spot: currency-neutral sales rose 7%, and instrument revenue grew more than 20% for the third straight quarter.
- Diagnostics returned to growth, led by Quality Systems and Diabetes, while Life Science ex-process chromatography rose 2.5% currency-neutral.
- Management reiterated full-year 2026 guidance and said it is focused on positive revenue growth in 2027 and further margin expansion.
Bio-Rad reported third-quarter 2026 net sales of approximately $656 million, versus $653 million in Q3 2025, up 0.5% reported and 0.7% currency-neutral. Life Science sales were $255 million, down 2.8% reported and 2.4% currency-neutral, while Clinical Diagnostics sales were approximately $402 million, up 2.7% reported and 2.8% currency-neutral. Consolidated gross margin was 50.1% on a GAAP basis versus 52.6% a year ago; non-GAAP gross margin was 54.5% versus 53.5%. Non-GAAP net income was $72 million, or $2.65 diluted EPS, versus $61 million, or $2.26 diluted EPS in the prior-year quarter. For 2026, management reaffirmed currency-neutral revenue growth of minus 3% to plus 0.5% and said full-year growth is expected near the midpoint; Life Science is guided to minus 3% to minus 1% and Clinical Diagnostics to minus 3% to plus 1%. They still expect Q4 revenue to ramp 5% to 6% sequentially on a reported basis, full-year non-GAAP gross margin in the upper half of 53% to 54%, non-GAAP operating margin in the upper half of 10% to 12%, and free cash flow of about $290 million to $340 million. They also said Q4 will include a $3 million sequential step-up in R&D and around $40 million of depreciation and amortization.
Norman Schwartz emphasized that Bio-Rad has been refocusing product development on market segments where it can compete best, and he highlighted the new ChemiDoc Pro launch as an example of faster execution and portfolio prioritization. He also said the Board is evaluating additions to bring more operational experience in life science tools and diagnostics. On Elliott Management, he said the dialogue remains active and productive, and the company believes it is broadly aligned on objectives. His tone was cautious but constructive, with encouragement about the progress being made.
Roop Lakkaraju focused on the quarter’s margin improvement and the company’s cost actions. He highlighted the 54.5% non-GAAP gross margin, 12.8% non-GAAP operating margin, and $72 million of non-GAAP net income, while noting that GAAP results were pressured by restructuring and a roughly $50 million noncash intangible asset impairment in Life Science. He reaffirmed the $80 million to $90 million restructuring program and said the expected $30 million to $35 million of savings is still intact, but the full benefit will really be in 2028. He also reiterated free cash flow guidance of $290 million to $340 million, said $210 million had been generated through nine months, and noted that tariff refunds would be recognized on a GAAP basis only.
Analysts pressed management on how to think about 2027 revenue given several lingering headwinds, and Roop said the company is aiming for positive growth in 2027, with margin expansion, but will provide formal 2027 guidance at year-end. Questions also focused on ddPCR momentum, where Jon said the new portfolio has broadened the customer base and remains an important growth driver, though he would not assume 20%+ instrument growth persists indefinitely. On China, management said Q3 was helped by timing, but the updated healthcare guidelines could create a middle-single-digit-million-dollar revenue impact in 2027, which they do not view as overly material. On capital allocation and Sartorius, Jon said the stake remains monetizable, buybacks will be opportunistic rather than systematic, and M&A interest is limited to deals of roughly $100 million to $500 million of revenue that add customer value and support margins.
The quarter showed several signs of operational improvement: first currency-neutral growth of the year, expanding non-GAAP gross margin, and stronger operating margin. ddPCR continues to gain traction with more than 20% instrument growth for the third straight quarter, while diagnostics returned to growth and management sees improving biopharma activity. Management also sounded optimistic that AI, innovation, and portfolio pruning can improve both product differentiation and productivity over time.
Management repeatedly flagged that end markets remain uneven, with continued pressure in academic and government funding, and it said the fourth-quarter outlook does not assume a recovery there. Process chromatography is expected to decline sequentially in Q4, ddPCR consumables pull-through has not yet normalized and could stay weak into 2027, and China pricing pressure plus new guidelines could weigh on 2027 revenue by a middle-single-digit-million-dollar amount. In addition, the company still expects significant restructuring savings to phase in only gradually, with the full benefit not realized until 2028.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 66.8%
- Shares Outstanding
- 26.89M
- Float Shares
- 17.98M
of shares held by institutions
409 13F filers
Buy/sell ratio 0.29. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for BIO, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Ro KhannaHouse · CA17 | Sell | Nov 3, 23 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Oct 26, 23 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Oct 2, 23 | Filing → |
| Lois FrankelHouse · FL22 | Sell | Sep 8, 23 | Filing → |
| Lois FrankelHouse · FL22 | Buy | Jun 28, 23 | Filing → |
| Lois FrankelHouse · FL22 | Buy | Jun 29, 23 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Jun 29, 23 | Filing → |
| Susie LeeHouse · NV03 | Sell | Nov 30, 22 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Nov 3, 22 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Oct 20, 22 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Jun 17, 22 | Filing → |
| Ro KhannaHouse · CA17 | Buy | May 10, 22 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Apr 13, 22 | Filing → |
| Thomas Hawley TubervilleSenate · AL | Sell | Mar 30, 22 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| First Eagle Investment Management, LLC | 2.46M | ▼ 150.64K |
| Vanguard Group Inc | 1.77M | ▼ 19.27K |
| Blackrock, Inc. | 1.70M | ▲ 18.87K |
| Dimensional Fund Advisors LP | 885.98K | ▼ 58.57K |
| Vanguard Capital Management LLC | 826.97K | ▼ 4.19K |
| Ariel Investments, LLC | 816.75K | ▲ 30.79K |
| Vanguard Portfolio Management LLC | 816.20K | ▼ 12.99K |
| Capital Research Global Investors | 596.24K | ▲ 152.76K |
| State Street Corp | 575.21K | ▲ 3.45K |
| Earnest Partners LLC | 567.82K | ▼ 12.94K |
| Bank Of America Corp | 490.41K | ▲ 45.45K |
| Ubs Am, A Distinct Business Unit Of Ubs Asset Management Americas LLC | 418.88K | ▼ 7.15K |
Held by 514 ETFs
Biggest fund positions in BIO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 10, 26 | ENLOE COURTNEY C | sell | 902 |
| Nov 9, 26 | DiVincenzo Jonathan P. | sell | 919 |
| Nov 9, 26 | BARRY JAMES | sell | 1,400 |
| Oct 24, 26 | DiVincenzo Jonathan P. | other | 1,869 |
| Oct 24, 26 | DiVincenzo Jonathan P. | other | 1,869 |
| Oct 24, 26 | DiVincenzo Jonathan P. | other | 951 |
| Oct 20, 26 | EVRAN SEDAT | other | 1,044 |
| Oct 20, 26 | EVRAN SEDAT | other | 487 |
| Oct 20, 26 | EVRAN SEDAT | other | 1,044 |
| Sep 6, 26 | Allison Schwartz | other | 92 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BIO coverage
Recent articles, reports, and earnings notes.
No research on BIO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BIO report →Insider Selling: Bio-Rad Laboratories (NYSE:BIO) EVP Sells $539,882.00 in Stock
defenseworld.net · Nov 15
Bio-Rad Laboratories (NYSE:BIO) Stock: Insider Courtney Enloe Sells 902 Shares
defenseworld.net · Nov 15
Bio-Rad Laboratories (NYSE:BIO) Stock: Insider Jonathan Divincenzo Sells 919 Shares
defenseworld.net · Nov 15
Bio-Rad Laboratories (NYSE:BIO) Stock: Insider James Barry Sells 1,400 Shares
defenseworld.net · Nov 15
Bio-Rad Laboratories, Inc. $BIO Stock Sold by Fisher Asset Management LLC
defenseworld.net · Nov 15
BIO-key Q3 Software License Fees Grew 39%, Its Third Consecutive Quarter of Double-Digit Growth, Driven Primarily by Momentum in the Middle East and Europe; Hosts Call Today at 10am ET
globenewswire.com · Nov 13
BIO GREEN MED SOLUTION REPORTS THIRD QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
globenewswire.com · Nov 12
BIO-key Enters Gaming / Hospitality Market with Contract from Major U.S. Casino Resort
globenewswire.com · Nov 11
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.